Generation of human neutralizing monoclonal antibodies against the 2009 pandemic H 1N 1 virus from peripheral blood memory B lymphocytes

The 2009 H 1N 1 influenza pandemic demonstrated the significance of a global health threat to human beings. Although pandemic H 1N 1 vaccines have been rapidly developed, passive serotherapy may offer superior immediate protection against infections in children, the elderly and immune-compromised pa...

Full description

Saved in:
Bibliographic Details
Published in:中国免疫学杂志：英文版 2013, Vol.10 (5), p.403-412
Main Author: Hao Wang Chi Ma Yanlai Lu Xu Ji Yongsheng Pang Fang Hua Lianxian Cui Denian Ba Wei He
Format: Article
Language:English
Subjects:
B淋巴细胞
Epstein-Barr病毒
人类健康
内存
单克隆抗体
外周血
流感疫苗
自身免疫性疾病
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The 2009 H 1N 1 influenza pandemic demonstrated the significance of a global health threat to human beings. Although pandemic H 1N 1 vaccines have been rapidly developed, passive serotherapy may offer superior immediate protection against infections in children, the elderly and immune-compromised patients during an influenza pandemic. Here, we applied a novel strategy based on Epstein-Barr virus （EBV）-immortalized peripheral blood memory B cells to screen high viral neutralizing monoclonal antibodies （MAbs） from individuals vaccinated with the 2009 pandemic H1N1 vaccine PANFLU.1. Through a massive screen of 13 090 immortalized memory B-cell clones from three selected vaccinees, seven MAbs were identified with both high viral neutralizing capacities and hemagglutination inhibition （HAl） activities against the 2009 pandemic H 1N 1 viruses. These MAbs may have important clinical implications for passive serotherapy treatments of infected patients with severe respiratory syndrome, especially children, the elderly and immunodeficient individuals. Our successful strategy for generating high-affinity MAbs from EBV-immortalized peripheral blood memory B ceils may also be applicable to other infectious or autoimmune diseases.
ISSN:1672-7681
2042-0226